Osaka-based drugmaker Shionogi & Co. said its experimental COVID-19 vaccine was found safe and effective in a study, potentially creating an indigenous supply source for the nation as it races to complete a booster drive in hopes of curbing future outbreaks.

The recombinant protein-based vaccine that was being tested as a booster shot met its primary endpoint in the Phase 2/3 trials, Shionogi said in a statement Friday announcing the interim report’s findings. There were no serious treatment-related adverse events, deaths or adverse events of special interest, it said.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.